Stockreport

Immunovant Announces Pricing of $121.2 Million Public Offering

Immunovant, Inc.  (IMVT) 
PDF NEW YORK, April 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients [Read more]